Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 4/20 | 0.43 |
| ▸ | HAO1 | Q9UJM8 | 4/20 | 0.43 |
| ▸ | XDH | P47989 | 2/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.39 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.39 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.38 |
| ▸ | LIFR | P42702 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30631925 | 1.00 | KMO (0.43) | KMOHAO1XDHMRGPRX4MCL1 | |
| Trifluoroacetic Acid SCHEMBL22608719 | 0.94 | HAO1 (0.39) | KMOHAO1XDHMRGPRX4MCL1 | |
| SCHEMBL30631919 | 0.90 | MRGPRX4 (0.49) | KMOHAO1MRGPRX4ALKBH1MAPT | |
| SCHEMBL22816228 | 0.90 | MRGPRX4 (0.49) | KMOHAO1MRGPRX4ALKBH1MAPT | |
| SCHEMBL22608317 | 0.87 | HAO1 (0.44) | HAO1MRGPRX4MCL1BCL2L1DHODH | |
| SCHEMBL22807359 | 0.85 | KMO (0.47) | KMOHAO1MRGPRX4NR1H4 | |
| Trifluoroacetic Acid SCHEMBL29514724 | 0.84 | MRGPRX4 (0.44) | KMOHAO1MRGPRX4MAPT | |
| Trifluoroacetic Acid SCHEMBL22608624 | 0.84 | MRGPRX4 (0.44) | KMOHAO1MRGPRX4MAPT | |
| SCHEMBL22608720 | 0.83 | CHUK (0.36) | KMOHAO1MCL1BCL2L1ALKBH1 | |
| SCHEMBL22608436 | 0.80 | PTGER4 (0.48) | HAO1MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2020257487-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | KMO 248/4885HAO1 9/4885XDH 1/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | KMO 248/4885HAO1 9/4885XDH 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.